Pediatric toxoplasmosis: 3D-printed, dose-flexible treatments for children and adults
Official title: Pediatric toxoplasmosis: Addressing unmet medical need with 3D printed dose flexible delivery systems of pyrimethamine, sulphadiazine and leucovorin
Funded at Texas A&m University Health Science Ctr · NIH-11377561 · Data updated 2026-11-12
A new 3D-printed, adjustable-dose treatment approach for toxoplasmosis could make pediatric and patient-specific therapy safer, affordable, and easier to administer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | September 11, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $641,810 |
| NIH project number | 5R01HD110552-03 |
| Project ID | NIH-11377561 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children with congenital or acquired toxoplasmosis and other patients requiring pyrimethamine-sulfadiazine-leucovorin therapy, including those where standard formulations are cost-prohibitive or unsuitable.
✕Less likely to help
Patients with toxoplasmosis who do not require dose-tailored therapy or have contraindications to the proposed drug combination may not benefit.
What this research studies
This grant proposes using 3D printing to create flexible, solid-dosage forms of pyrimethamine, sulfadiazine, and leucovorin to treat toxoplasmosis in children and other patients. The goal is to improve dose accuracy, stability, and bioavailability while reducing cost and reliance on compounded or adult-formulations. The work envisions hospital-based manufacturing of personalized doses to fit individual patient needs for both congenital and acquired toxoplasmosis. If successful, this approach could streamline pediatric treatment and potentially expand access to life-saving therapy. The project is led by Texas A&M University Health Science Center and involves multidisciplinary collaboration to translate a dental/industrial printing approach to a clinical setting.
Why it matters
Potential benefit: Patients could receive safer, more affordable, and precisely dosed therapy tailored to their age and weight.
How similar studies have gone: Previous work suggests 3D printing can enable dose-tailored, stable solid-dose forms; clinical translation is still under investigation for pediatric infectious diseases.
Where this research is happening
-
Texas A&m University Health Science Ctr
College Station, United States Active
Researchers
- Principal investigator: Khan, Mansoor a — Texas A&m University Health Science Ctr
- Study coordinator: Khan, Mansoor a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.